By Nick Paul Taylor – Fierce Biotech –
BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the sector.
Garnier worked as CEO of GSK, then called GlaxoSmithKline, from 2000 to 2008. Toward the end of his time heading up the company, Garnier oversaw the $720 million acquisition of Sirtris Pharmaceuticals. The biotech landed the buyout on the basis of evidence that resveratrol, a molecule in red wine, and other sirtuin-targeted drugs could extend healthy life spans.
